The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Milvexian for the Prevention of Venous Thromboembolism
Open accessAbstract
BACKGROUND: Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants. Additional data are needed regarding the efficacy and safety of milvexian, an oral factor XIa inhibitor. METHODS: In this parallel-group, phase 2 trial, we randomly assigned 1242 patients undergoing knee arthroplasty to receive one of seven postoperative regimens of milvexian (25 mg, 50 mg, 100 mg, or 200 mg twice daily or 25 mg, 50 mg, or 200 mg once daily) or enoxaparin (40 mg once daily). The primary efficacy outcome was venous thromboembolism (which was a composite of asymptomatic deep-vein thrombosis, confirmed symptomatic venous thromboembolism, or death from any cause). The principal safety outcome was bleeding. RESULTS: Among the patients receiving milvexian twice daily, venous thromboembolism developed in 27 of 129 (21%) taking 25 mg, in 14 of 124 (11%) taking 50 mg, in 12 of 134 (9%) taking 100 mg, and in 10 of 131 (8%) taking 200 mg. Among those receiving milvexian once daily, venous thromboembolism developed in 7 of 28 (25%) taking 25 mg, in 30 of 127 (24%) taking 50 mg, and in 8 of 123 (7%) taking 200 mg, as compared with 54 of 252 patients (21%) taking enoxaparin. The dose-response relationship with twice-daily milvexian was significant (one-sided P<0.001), and the 12% incidence of venous thromboembolism with twice-daily milvexian was significantly lower than the prespecified benchmark of 30% (one-sided P<0.001). Bleeding of any severity occurred in 38 of 923 patients (4%) taking milvexian and in 12 of 296 patients (4%) taking enoxaparin; major or clinically relevant nonmajor bleeding occurred in 1% and 2%, respectively; and serious adverse events were reported in 2% and 4%, respectively. CONCLUSIONS: Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. (Funded by Bristol Myers Squibb and Janssen Research and Development; AXIOMATIC-TKR ClinicalTrials.gov number, NCT03891524.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Self-citationFactor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Büller, H. R., Bethune, C., Bhanot, S., Gailani, D., Monia, B. P., Raskob, G. E., Segers, A., Verhamme, P., & Weitz, J. I. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405760 · Cited by 630
Self-citationAbelacimab for Prevention of Venous Thromboembolism
Verhamme, P., Yi, B. A., Segers, A., Salter, J., Bloomfield, D., Büller, H. R., Raskob, G. E., & Weitz, J. I. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105872 · Cited by 306
Self-citationPreis, M., Hirsch, J., Kotler, A., Zoabi, A., Stein, N., Rennert, G., & Saliba, W. (2017) · Blood · doi:10.1182/blood-2016-09-742262 · Cited by 246
Steinberg, B. A., Gao, H., Shrader, P., Pieper, K., Thomas, L., Camm, A. J., Ezekowitz, M. D., Fonarow, G. C., Gersh, B. J., Goldhaber, S., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.08.011 · Cited by 217
Self-citationFactor XI Inhibition to Uncouple Thrombosis From Hemostasis
Hsu, C., Hutt, E., Bloomfield, D. M., Gailani, D., & Weitz, J. I. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.010 · Cited by 191
Self-citationModel‐based dose finding under model uncertainty using general parametric models
Pinheiro, J., Bornkamp, B., Glimm, E., & Bretz, F. (2014) · Statistics in Medicine · doi:10.1002/sim.6052 · Cited by 163
Fuji, T., FUJITA, S., TACHIBANA, S., & Kawai, Y. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04021.x · Cited by 137
Sanghai, S., Wong, C. H., Wang, Z., Clive, P. H., Tran, W., Waring, M. E., Goldberg, R. J., Hayward, R., Saczynski, J. S., & McManus, D. D. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014108 · Cited by 123
Cited by
Piccini, J. P., Caso, V., Connolly, S. J., Fox, K. A. A., Oldgren, J., Jones, W. S., Gorog, D. A., Durdil, V., Viethen, T., Neumann, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00456-1 · Cited by 323
Kumbhani, D. J., Armbruster, A. L., Cheng, R. K., Chrispin, J., Fischer, U., Holbrook, A. M., Joglar, J., & Sevestre, M.-A. (2026) · JACC · doi:10.1016/j.jacc.2026.05.033 · Cited by 2
Metadata
- Authors
- Weitz, J. I., Strony, J., Ageno, W., Gailani, D., Hylek, E. M., Lassen, M. R., Mahaffey, K. W., Notani, R. S., Roberts, R., Segers, A., & Raskob, G. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-02
- Volume
- 385
- Issue
- 23
- Pages
- 2161-2172
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3212517452
- Cited by
- 269
- References
- 9
- FWCI
- 31.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.